saker falcon
Biotech

Ipsen fails to land pivotal rare disease trial

Ipsen’s miss follows Regeneron's phase 3 win in the same ultrarare indication. Regeneron said it planned for a FDA submission by the end of 2025.
Gabrielle Masson Dec 19, 2025 3:37pm
Orange star symbol glowing amid black star symbols on black background

Fierce Biotech's 2025 must-reads

Dec 19, 2025 7:00am
BD Bilal Muhsin

BD’s Bilal Muhsin on what good AI can still do for healthcare

Dec 19, 2025 2:36pm
Fierce Fundraising Tracker image 2025

Fierce Biotech Fundraising Tracker: Syneron, Atavistik & more

Dec 19, 2025 2:00pm
Space shuttle takes off on background of blue sky

VC Aditum launches new biotech for foray with Fosun

Dec 19, 2025 11:25am
brain neurostimulation

Following Medtronic, J&J nets liquid embolic nod in brain bleeds

Dec 19, 2025 10:51am
More News

2 pharmas turn Scrooge, returning biotechs' unwanted gifts

Dec 19, 2025 10:44am
Fierce Pharma

Cybin alters state to become Helus Pharma for Nasdaq trip

Dec 19, 2025 10:30am

Altimmune eyes phase 3 MASH trial as weight loss deepens

Dec 19, 2025 8:30am

Pfizer RNA leader runs to Replicate—Chutes & Ladders

Dec 19, 2025 8:30am